Vale Biolabs lands $183,000 Venture Kick grant for brain-disease research
What's the deal? Swiss biotech Vale BiolabsDealroom has a profile for this one. Try Dealroom → has received a US$137.5K (roughly $183,000) grant from Venture KickDealroom has a profile for this one. Try Dealroom → to advance its platform for studying brain diseases and evaluating potential treatments.
What does it do? Founded in 2026 and based in Zurich, Vale Biolabs combines lab-grown human brain tissue, automation, and predictive AI to help researchers understand how the brain responds to drugs. It builds standardised human brain organoids — miniature tissue models — and tracks their structure, activity, and molecular responses before and after exposure to treatments.
What's the endgame? The company wants to let drug developers test on human brain tissue earlier, flagging promising therapies and likely failures before clinical trials. Its technology targets conditions including rare brain disorders and neurodegenerative diseases such as Alzheimer's and Parkinson's.
Why now? Preclinical research leans heavily on animal testing, and gaps between animal and human biology make it hard to predict how drugs will perform in patients — a factor in costly clinical-trial failures.
The grant will fund further development of Vale's automated platform, expansion of its organoid models, and datasets to train and validate its predictive AI. It will also support collaborations with research and industry partners.
The signal: The award is an early-stage grant, not a venture round. It arrives amid rising European interest in neuroscience: Germany's Exciva raised €51 million in January to push an Alzheimer's treatment into Phase 2, and Belgium's Remynd secured €3.5 million in September for a Phase 1b trial. Against those sums, Vale's grant is a modest step toward building and validating its research rather than a near-term treatment breakthrough.
Read more: Tech.eu
Image credit: Generated with Gemini